Future Direction of Renal Positron Emission Tomography

Seminars in Nuclear Medicine - Tập 36 Số 1 - Trang 36-50 - 2006
Zsolt Szabó1, Jinsong Xia, William B. Mathews, Phillip R. Brown
1Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. [email protected]

Tóm tắt

Từ khóa


Tài liệu tham khảo

Hewitt, 2004, Discovery of protein biomarkers for renal diseases, J Am Soc Nephrol, 15, 1677, 10.1097/01.ASN.0000129114.92265.32

Lorenz, 1992, Quantitative imaging of renal blood flow and function, Invest Radiol, 27, S109, 10.1097/00004424-199212002-00019

Romero, 2000, Novel noninvasive techniques for studying renal function in man, Semin Nephrol, 20, 456

Townsend, 2004, Physical principles and technology of clinical PET imaging, Ann Acad Med Singapore, 33, 133, 10.47102/annals-acadmedsg.V33N2p133

Judenhofer, 2005, Evaluation of high performance data acquisition boards for simultaneous sampling of fast signals from PET detectors, Phys Med Biol, 50, 29, 10.1088/0031-9155/50/1/003

Kontaxakis, 2002, Iterative image reconstruction for clinical PET using ordered subsets, median root prior, and a web-based interface, Mol Imaging Biol, 4, 219, 10.1016/S1536-1632(02)00004-5

Gutman, 2003, Optimisation of the OS-EM algorithm and comparison with FBP for image reconstruction on a dual-head camera, Eur J Nucl Med Mol Imaging, 30, 1510, 10.1007/s00259-003-1246-6

Koepfli, 2004, CT attenuation correction for myocardial perfusion quantification using a PET/CT hybrid scanner, J Nucl Med, 45, 537

Kaatee, 1997, Renal artery stenosis, Radiology, 205, 121, 10.1148/radiology.205.1.9314973

Kim, 1998, Renal artery evaluation, J Vasc Interv Radiol, 9, 553, 10.1016/S1051-0443(98)70320-3

Carlos, 2003, Incorporating patient-centered outcomes in the analysis of cost-effectiveness, AJR Am J Roentgenol, 181, 1653, 10.2214/ajr.181.6.1811653

Alpert, 2002, Mapping of local renal blood flow with PET and H(2)(15)O, J Nucl Med, 43, 470

Fine, 2000, Parenchymal mean transit time analysis of 99mTc-DTPA captopril renography, J Nucl Med, 41, 1627

Szabo, 1985, Model identification and estimation of organ-function parameters using radioactive tracers and the impulse-response function, Eur J Nucl Med, 11, 265, 10.1007/BF00279082

Torsello, 1985, Experimental studies on renal transfer function. Effects of renal artery stenosis and occlusion, Edizioni Minerva Medica, 125

Yamashita, 1988, Quantitative measurement of renal function using Ga-68-EDTA, Tohoku J Exp Med, 155, 207, 10.1620/tjem.155.207

Gjedde, 1995, Compartmental analysis, 451

Logan, 2000, Graphical analysis of PET data applied to reversible and irreversible tracers, Nucl Med Biol, 27, 661, 10.1016/S0969-8051(00)00137-2

Nitzsche, 1993, Quantification and parametric imaging of renal cortical blood flow in vivo based on Patlak graphical analysis, Kidney Int, 44, 985, 10.1038/ki.1993.340

Gjedde, 1985, Transient analysis of irreversible and reversible tracer binding in human brain, 223

Patlak, 1983, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data, J Cereb Blood Flow Metab, 3, 1, 10.1038/jcbfm.1983.1

Szabo, 1998, Investigation of angiotensin II/AT1 receptors with carbon-11-L-159, 884, J Nucl Med, 39, 1209

Hutchins, 2001, What is the best approach to quantify myocardial blood flow with pet?, J Nucl Med, 42, 1183

Mullani, 1990, Feasibility of measuring first pass extraction and flow with rubidium-82 in the kidneys, Am J Physiol Imaging, 5, 133

Tamaki, 1986, Serial analysis of renal blood flow by positron tomography with rubidium-82, Am J Physiol, 251, H1024

Young, 1994, Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model, Eur J Nucl Med, 21, 336, 10.1007/BF00947969

Shelton, 1990, Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography, Circulation, 82, 990, 10.1161/01.CIR.82.3.990

Young, 2002, R: Tissue blood flow estimation with copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) and PET, J Nucl Biol Med, 38, 89

Killion, 1993, Positron emission tomography, J Urol, 150, 1064, 10.1016/S0022-5347(17)35687-2

Goethals, 2000, 55Co-EDTA for renal imaging using positron emission tomography (PET), Nucl Med Biol, 27, 77, 10.1016/S0969-8051(99)00077-3

Karanikas, 2002, ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis, Eur J Nucl Med Mol Imaging, 29, 312, 10.1007/s00259-001-0707-z

Clorius, 1997, The exercise renogram and its interpretation, J Nucl Med, 38, 1146

Imanishi, 1998, Aspirin renography in diagnosis of unilateral renovascular hypertension, Hypertens Res, 21, 209, 10.1291/hypres.21.209

Shreve, 1995, Carbon-11-acetate PET imaging in renal disease, J Nucl Med, 36, 1595

Oyama, 2003, 11C-acetate PET imaging of prostate cancer, J Nucl Med, 44, 549

Kotzerke, 2003, Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer, Nuclearmedizin, 42, 25, 10.1055/s-0038-1623902

Seltzer, 2004, Radiation dose estimates in humans for (11)C-acetate whole-body PET, J Nucl Med, 45, 1233

Nabulsi, 2005, [(11)C]Glycylsarcosine, Bioorg Med Chem, 13, 2993, 10.1016/j.bmc.2005.02.002

Han, 2000, Targeted prodrug design to optimize drug delivery, AAPS PharmSci, 2, E6, 10.1208/ps020106

Terada, 2004, Peptide transporters, Curr Drug Metab, 5, 85, 10.2174/1389200043489153

Nielsen, 2003, Di/tri-peptide transporters as drug delivery targets, Curr Drug Targets, 4, 373, 10.2174/1389450033491028

Theis, 2002, Synthesis and characterization of high affinity inhibitors of the H+/peptide transporter PEPT2, J Biol Chem, 277, 7287, 10.1074/jbc.M105028200

Padhy, 1993, Clinical evaluation of 99mTc diaminocyclohexane, a renal tubular agent with cationic transport, Nephron, 65, 294, 10.1159/000187491

Wild, 2005, 68Ga-DOTANOC, Eur J Nucl Med Mol Imaging, 32, 724, 10.1007/s00259-004-1697-4

Prakash, 1996, Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use, Nucl Med Biol, 23, 543, 10.1016/0969-8051(96)00038-8

Jones-Wilson, 1998, The in vivo behavior of copper-64-labeled azamacrocyclic complexes, Nucl Med Biol, 25, 523, 10.1016/S0969-8051(98)00017-1

Yoo, 2005, A potential Dubin-Johnson syndrome imaging agent, Mol Imaging, 4, 18, 10.1162/15353500200504160

Paulusma, 1997, A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome, Hepatology, 25, 1539, 10.1002/hep.510250635

Sun, 2004, In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands, Nucl Med Biol, 31, 1051, 10.1016/j.nucmedbio.2004.08.011

Heilig, 1997, Glucose transporters of the glomerulus and the implications for diabetic nephropathy, Kidney Int Suppl, 60, S91

Wright, 2001, Renal Na(+)-glucose cotransporters, Am J Physiol Renal Physiol, 280, F10, 10.1152/ajprenal.2001.280.1.F10

Bormans, 2003, Synthesis and biologic evaluation of (11)c-methyl-d-glucoside, a tracer of the sodium-dependent glucose transporters, J Nucl Med, 44, 1075

de Groot, 2003, Synthesis of 18F-fluoroalkyl-beta-D-glucosides and their evaluation as tracers for sodium-dependent glucose transporters, J Nucl Med, 44, 1973

Shirota, 2001, Characterization of novel kidney-specific delivery system using an alkylglucoside vector, J Pharmacol Exp Ther, 299, 459

Hwang, 1991, Positron-labeled angiotensin-converting enzyme (ACE) inhibitor, J Nucl Med, 32, 1730

Markham, 1995, In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. I: Theory and error analysis, J Appl Physiol, 78, 1158, 10.1152/jappl.1995.78.3.1158

Schuster, 1995, In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. II: Implementation and application, J Appl Physiol, 78, 1169, 10.1152/jappl.1995.78.3.1169

Matarrese, 2004, 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat, Bioorg Med Chem, 12, 603, 10.1016/j.bmc.2003.10.054

Akcay, 2004, Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction, Transplantation, 78, 892, 10.1097/01.TP.0000134972.81306.B1

Kaschina, 2003, Angiotensin AT1/AT2 receptors, Blood Press, 12, 70, 10.1080/08037050310001057

Nickenig, 1998, Salt induces vascular AT1 receptor overexpression in vitro and in vivo, Hypertension, 31, 1272, 10.1161/01.HYP.31.6.1272

Strehlow, 2000, Angiotensin AT1 receptor over-expression in hypercholesterolaemia, Ann Med, 32, 386, 10.3109/07853890008995944

Sodhi, 2003, Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells, Am J Physiol Heart Circ Physiol, 284, H846, 10.1152/ajpheart.00625.2002

Dumont, 1999, Involvement of central angiotensin receptors in stress adaptation, Neuroscience, 93, 877, 10.1016/S0306-4522(99)00206-7

Wu, 2003, Estrogen regulates adrenal angiotensin type 1 receptors by modulating AT1 receptor translation, Endocrinology, 144, 3251, 10.1210/en.2003-0015

Harrison-Bernard, 2003, Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity, Hypertension, 42, 1157, 10.1161/01.HYP.0000102180.13341.50

Nickenig, 1998, Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms, Circulation, 98, 2453, 10.1161/01.CIR.98.22.2453

Nickenig, 1997, Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia, Eur J Med Res, 2, 285

Aneja, 2004, Hypertension and obesity, Recent Prog Horm Res, 59, 169, 10.1210/rp.59.1.169

Prasad, 2004, Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome, Circulation, 110, 1507, 10.1161/01.CIR.0000141736.76561.78

Ortlepp, 2002, Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia, Eur J Pharmacol, 436, 145, 10.1016/S0014-2999(01)01587-4

Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9

Chertin, 2002, Upregulation of angiotensin II receptors in reflux nephropathy, J Pediatr Surg, 37, 251, 10.1053/jpsu.2002.30266

Mento, 1998, Increased expression of glomerular AT1 receptors in rats with myocardial infarction, Am J Physiol, 275, H1247

Modrall, 1995, Upregulation of angiotensin II type 1 receptor gene expression in chronic renovascular hypertension, J Surg Res, 59, 135, 10.1006/jsre.1995.1144

Nickenig, 2002, Central role of the AT(1)-receptor in atherosclerosis, J Hum Hypertens, 16, S26, 10.1038/sj.jhh.1001436

Kim, 1996, In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist, J Nucl Med, 37, 307

Mathews, 2004, A novel radioligand for imaging the AT1 angiotensin receptor with PET, Nucl Med Biol, 31, 571, 10.1016/j.nucmedbio.2003.10.014

Szabo, 2001, Use of positron emission tomography to study AT1 receptor regulation in vivo, J Am Soc Nephrol, 12, 1350, 10.1681/ASN.V1271350

Gibson, 1994, Receptor binding radiotracers for the angiotensin II receptor, Nucl Med Biol, 21, 593, 10.1016/0969-8051(94)90024-8

Owonikoko, 2003, In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET, J Nucl Med, 45, 94

Goodfriend, 2000, Angiotensin receptors, Am J Hypertens, 13, 442, 10.1016/S0895-7061(99)00212-5

de Gasparo, 2000, International union of pharmacology. XXIII: The angiotensin II receptors, Pharmacol Rev, 52, 415

Hamill, 1996, Development of [11C]L-159, 884, Appl Radiat Isotopes, 47, 211, 10.1016/0969-8043(95)00273-1

Hong, 1998, The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist, Fundam Clin Pharmacol, 12, 64, 10.1111/j.1472-8206.1998.tb00925.x

Lee, 1999, In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist, J Cardiovasc Pharmacol, 33, 375, 10.1097/00005344-199903000-00005

Owonikoko, 2003, In vivo investigation of estrogen regulation of adrenal and renal angiotensin AT1 receptor expression by PET, J Nucl Med, 45, 94

Guyton, 1984, Some problems and solutions for modeling overall cardiovascular regulation, Mathematical Biosci, 72, 141, 10.1016/0025-5564(84)90107-X

Anderson, 1990, Development of hypertension from unilateral renal artery stenosis in conscious dogs, Hypertension, 16, 441, 10.1161/01.HYP.16.4.441

Tsuji, 1992, Patterns of renal function in hypertension due to unilateral renal artery occlusion, Clin Exp Hypertens A, 14, 1067

Admiraal, 1993, Regional angiotensin II production in essential hypertension and renal artery stenosis, Hypertension, 21, 173, 10.1161/01.HYP.21.2.173

Mai, 1995, Expression of angiotensin-converting enzyme in renovascular hypertensive rat kidney, Hypertension, 25, 674X, 10.1161/01.HYP.25.4.674

Haefliger, 1995, Renin and angiotensin II receptor gene expression in kidneys of renal hypertensive rats, Hypertension, 26, 733, 10.1161/01.HYP.26.5.733

Wilkes, 1988, Intrarenal renin-angiotensin system modulates glomerular angiotensin receptors in the rat, Am J Physiol, 254, F345

Lu, 1996, Variation of intrarenal angiotensin II and angiotensin II receptors by acute renal ischemia in the aged rat, Renal Failure, 18, 19, 10.3109/08860229609052771

Regitz-Zagrosek, 1996, Molecular biology of angiotensin receptors and their role in human cardiovascular disease, J Mol Med, 74, 233, 10.1007/BF00196577

Ernst, 1976, Relatonship between collateral development and renin in experimental renal artery stenosis, Surgery, 80, 252

Llorens-Cortes, 1994, Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis, Hypertension, 24, 538, 10.1161/01.HYP.24.5.538

Unger, 2002, The role of the renin-angiotensin system in the development of cardiovascular disease, Am J Cardiol, 89, 3A, 10.1016/S0002-9149(01)02321-9

Schieffer, 2000, Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques, Circulation, 101, 1372, 10.1161/01.CIR.101.12.1372

Pantuck, 2002, CL1-SR39, J Urol, 168, 1193, 10.1016/S0022-5347(05)64624-1

Textor, 2004, Ischemic nephropathy, J Am Soc Nephrol, 15, 1974, 10.1097/01.ASN.0000133699.97353.24

Gerhard, 2005, Evolution of microglial activation in patients after ischemic stroke, Neuroimage, 24, 591, 10.1016/j.neuroimage.2004.09.034

Jemal, 2004, Cancer statistics, 2004, CA Cancer J Clin, 54, 8, 10.3322/canjclin.54.1.8

Pantuck, 2001, The changing natural history of renal cell carcinoma, J Urol, 166, 1611, 10.1016/S0022-5347(05)65640-6

Chow, 1999, Rising incidence of renal cell cancer in the United States, JAMA, 281, 1628, 10.1001/jama.281.17.1628

Sorger, 2003, [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO), Nucl Med Biol, 30, 317, 10.1016/S0969-8051(02)00442-0

Rasey, 1987, Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells, Radiat Res, 111, 292, 10.2307/3576986

Rasey, 1996, Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole, Int J Radiat Oncol Biol Phys, 36, 417, 10.1016/S0360-3016(96)00325-2

Koh, 1992, Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole, Int J Radiat Oncol Biol Phys, 22, 199, 10.1016/0360-3016(92)91001-4

Fujibayashi, 1997, A Copper-62-ATSM, J Nucl Med, 38, 1155

Gronroos, 2001, Pharmacokinetics of [18F]FETNIM, J Nucl Med, 42, 1397

Evans, 2000, Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1, J Nucl Med, 41, 327

Rajendran, 2003, [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas, Eur J Nucl Med Mol Imaging, 30, 695, 10.1007/s00259-002-1096-7

Dolbier, 2001, [18F]-EF5, a marker for PET detection of hypoxia, Appl Radiat Isotopes, 54, 73, 10.1016/S0969-8043(00)00102-0

Nishikibe, 1999, Pharmacological properties of J-104132 (L-753, 037), a potent orally active, mixed ETA/ATB endothelin receptor antagonist, J Pharmacol Exp Ther, 289, 1262

Aleksic, 2001, In vivo labeling of endothelin receptors with [11C]L-735, 037, J Nucl Med, 42, 1274

Chen, 2004, Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide, Mol Imaging, 3, 96, 10.1162/1535350041464892

Haubner, 2005, Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD, PLoS Med, 2, e70, 10.1371/journal.pmed.0020070